At the archive date, ABBOTT LABORATORIES was expected to release its Q3 2026 10-Q filing on October 13, 2026, before market open. Last quarter: Abbott Laboratories reported 13.0% net sales growth to $12.6B in Q2 2026, driven primarily by the $20.6B acquisition of Exact Sciences (now reported as Cancer Diagnostics within Diagnostic Products), alongside high single-digit growth in Medical Devices and Established Pharmaceutical Products, while gross margin slightly compressed to 52.5% due to acquisition-related intangible amortization.
EPS Estimate
$1.43
Revenue Estimate
$13.13B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the ABT page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Abbott completed the $20.6 billion acquisition of Exact Sciences on March 23, 2026, funded primarily through $20.0 billion in newly issued long-term debt. Exact Sciences' results are now reported as 'Cancer Diagnostics' within the Diagnostic Products segment, contributing approximately $1.0 billion in net sales for the first six months of 2026, and driving Diagnostic Products segment growth of 42.3% in Q2 2026 (41.3% excluding FX).
For the six months ended June 30, 2026, Medical Devices grew 8.0% excluding FX (led by double-digit growth in Electrophysiology +13.0%, Rhythm Management +10.9%, and Heart Failure +10.4%), and Established Pharmaceutical Products grew 8.9% excluding FX. In contrast, Nutritional Products declined 5.6% excluding FX due to lower volumes in adult and U.S. pediatric nutritionals.
Diabetes Care sales increased 8.2% excluding FX in the first six months of 2026, driven by continuous glucose monitoring (CGM) systems, which totaled $4.1 billion versus $3.6 billion in the prior-year period, an 8.6% increase excluding FX. In May 2026, Abbott also secured a CE Mark for Libre Duo, its dual glucose-ketone biowearable sensor.
Revenue
$12.59B
+13.02% YoY
EPS (Diluted)
$0.53
-47.52% YoY
Operating Income
$1.69B
-17.50% YoY
Add ABT to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.